Psychemedics Net Income/Loss 2010-2024 | PMD

Psychemedics net income/loss from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
Psychemedics Annual Net Income/Loss
(Millions of US $)
2024 $-2
2023 $-4
2022 $-1
2021 $-1
2020 $-4
2019 $2
2018 $5
2017 $6
2016 $7
2015 $2
2014 $3
2013 $4
2012 $3
2011 $3
2010 $3
2009 $2
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $0.000B $0.020B
Psychemedics Corporation provides testing services for the detection of abused substances through the analysis of hair samples. Their testing methods utilize a patented technology for performing immunoassays on enzymatically dissolved hair samples with confirmation testing by mass spectrometry.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $19.885B 19.59
Encompass Health (EHC) United States $12.215B 25.89
DaVita (DVA) United States $10.944B 15.39
Chemed (CHE) United States $8.456B 26.58
Elanco Animal Health (ELAN) United States $6.566B 14.06
Option Care Health (OPCH) United States $5.418B 24.15
RadNet (RDNT) United States $4.551B 288.86
Amedisys (AMED) United States $3.089B 20.78
LifeStance Health (LFST) United States $2.271B 0.00
Addus HomeCare (ADUS) United States $2.044B 22.44
Astrana Health (ASTH) United States $1.505B 37.29
U.S Physical Therapy (USPH) United States $1.211B 31.26
Aveanna Healthcare Holdings (AVAH) United States $1.112B 63.33
Pennant (PNTG) United States $1.025B 37.65
Atai Life Sciences (ATAI) Germany $0.369B 0.00
Daxor (DXR) United States $0.037B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.022B 0.00
Ontrak (OTRK) United States $0.007B 0.00